Collaboration Agreement
BiondVax Signs Definitive Collaboration Agreement for the Development of a Pipeline of Innovative Nanosized Antibody (NanoAb) Therapies
BiondVax
PR-M03-22-11Mar 24, 2022
PR-M10-18-NI-081
BiondVax Receives €8M From the European Investment Bank (EIB) in Support of Manufacturing Facility and Ongoing Phase 3 Clinical Trial
BiondVax
InvestmentOct 24, 2018
Clinical Trial
First Participant Enrolled in BiondVax's Universal Flu Vaccine Pivotal Phase 3 Clinical Trial
BiondVax
PR-M08-18-NI-095Aug 22, 2018